|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||41.65 - 42.15|
|52 Week Range||35.05 - 44.54|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.
NEW YORK, Jan. 03, 2018-- WisdomTree, an exchange-traded fund and exchange-traded product sponsor and asset manager, today announced the addition of the WisdomTree Emerging Markets ex-State-Owned Enterprises ...
While a rise in interest rates would diminish the attractiveness of dividend stocks, investors are chasing these on optimism surrounding the biggest tax overhaul in decades.